Lung Cancer

A malignant growth in the lungs is referred to as lung cancer or bronchogenic carcinoma and is the most common form of cancer in humans. The cancer cells can spread through the blood system and the lymphatic system and so reach other organs where they can form metastatic tumours. There are different types of lung cancer: non-small cell lung cancer, which accounts for 85% of all cases, and small cell lung cancer which is rarer.

The first signs of lung cancer are usually uncharacteristic and can be easily mistaken for flu symptoms, such as coughing and breathing difficulties. If these symptoms are accompanied by weight loss, fever, coughing up blood, this is often an indication that the cancer has already advanced.

Treatment based on the latest scientific findings

Thanks to many new forms of therapy, lung cancer can now be treated more specifically than just a few years ago. Which therapy is best suited depends, for instance, on the type of lung cancer and how far the disease has progressed. Generally speaking, there are four different treatment options which can be combined as needed: surgery, radiotherapy, chemotherapy and targeted cancer therapy using "biologicals".

Treatment at the CIO ∙ Cancer Center Cologne is based on the latest scientific findings and on the patient's very own personal medical history (individualised therapy). Doctors from different disciplines work together on the diagnosis and therapy in order to jointly draw up a specific treatment plan. Depending on the type of therapy chosen, patients receive in-patient treatment or attend the out-patient center.

Knowledge leadership at the CIO ∙ Cancer Center Cologne

The CIO ∙ Cancer Center Cologne is involved in research into new forms of therapy for lung cancer. Since 2006, eight departments and units of University Hospital Cologne have been co-operating closely in the so-called Lung Cancer Group Cologne (LCGC). The CIO ∙ Cancer Center Cologne is particularly committed to personalised therapy and has set up it own study platform so that the latest genetic research findings can be included in clinical trials. Research work also focuses on the development of so-called biomarkers for early detection of lung cancer.

The lung cancer research results of the CIO ∙ Cancer Center Cologne have received international recognition. Our patients benefit from the close ties with science because this provides them with faster access to new forms of therapy.